SLS SELLAS Life Sciences Group, Inc. - Common Stock
Acerca de SELLAS Life Sciences Group, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Galena Biopharma, Inc. was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc..
Leer más
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigation their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
SLS Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
SLS Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
SLS Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
- Compra fuerte 1 16,7%
- Compra 4 66,7%
- Mantener 1 16,7%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
2 analistas · 2026-08-14Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 31 de marzo de 2026 | $-0.05 | $-0.04 | -0.01% |
| 31 de diciembre de 2025 | $-0.05 | $-0.07 | 0.02% |
| 30 de septiembre de 2025 | $-0.06 | $-0.07 | 0.01% |
| 30 de junio de 2025 | $-0.07 | $-0.08 | 0.01% |
| 31 de marzo de 2025 | $-0.07 | $-0.11 | 0.04% |
| 31 de diciembre de 2024 | $-0.08 | $-0.11 | 0.03% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| COAG | — | — | — | — | — | — |
| KLRA | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 15
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
Balance general 22
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
Flujo de Efectivo 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
Liquidez y Solvencia 4
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
Eficiencia 1
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
Tasas de Crecimiento 1
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
Valoración (TTM) 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
Estado de resultados 12
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
Balance general 15
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
Flujo de Efectivo 7
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
Liquidez y Solvencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
Eficiencia 1
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Valoración (TTM) 9
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $1M | · | $1M | |
| Net Income TTM | $-31M | $-28M | · | $-26M | $-27M | $-30M | · | $-33M | $-35M | $-39M | · | $-36M | $-35M | $-43M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -64.2 | -16.9 | · | -5.4 | -5.9 | -2.1 | · | -1.6 | -1.2 | -0.8 | · | -1.1 | -1.0 | -0.6 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 40.5 | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.6% | -5.9% | · | -18.6% | -16.9% | -47.2% | · | -61.6% | -82.3% | -130.7% | · | -88.4% | -97.5% | -158.7% | · | -111.4% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | — | — | $0 | $1M | $8M |
| Margen Operativo % | — | — | — | -4195.0% | -332.8% |
| Beneficio neto | $-27M | $-31M | $-37M | $-41M | $-21M |
| EPS Diluido | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| Ratio Rápido | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 231 declarantes · $1.2B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 87 (+24 vs trimestre anterior) | 19 (+4 vs trimestre anterior) | 70 (+12 vs trimestre anterior) | 38 (+15 vs trimestre anterior) | +39.9M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| STATE STREET CORP | $191 829 196 | 12 996 558 | 15,97% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $121 417 310 | 8 226 105 | 10,11% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105 640 272 | 7 157 200 | 8,79% | Opción de compra |
| Anson Funds Management LP | $66 420 000 | 4 500 000 | 5,53% | Acciones |
| CITADEL ADVISORS LLC | $64 157 292 | 4 346 700 | 5,34% | Opción de compra |
| GEODE CAPITAL MANAGEMENT, LLC | $61 905 400 | 4 193 009 | 5,15% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61 832 592 | 4 189 200 | 5,15% | Opción de venta |
| CITADEL ADVISORS LLC | $33 333 984 | 2 258 400 | 2,77% | Opción de venta |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31 897 821 | 2 161 099 | 2,66% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30 266 812 | 2 050 597 | 2,52% | Acciones |
| JONES FINANCIAL COMPANIES LLLP | $28 553 511 | 2 304 561 | 2,38% | Acciones |
| VANGUARD GROUP INC | $27 868 421 | 7 392 154 | 2,32% | Acciones |
| Anson Funds Management LP | $27 245 484 | 1 845 900 | 2,27% | Opción de venta |
| PERCEPTIVE ADVISORS LLC | $22 140 000 | 1 500 000 | 1,84% | Opción de venta |
| VANGUARD FIDUCIARY TRUST CO | $19 707 050 | 1 335 166 | 1,64% | Acciones |
| Sio Capital Management, LLC | $18 165 132 | 1 230 700 | 1,51% | Opción de venta |
| BNP PARIBAS FINANCIAL MARKETS | $15 823 045 | 1 072 022 | 1,32% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $13 372 560 | 906 000 | 1,11% | Opción de venta |
| BARCLAYS PLC | $11 831 616 | 801 600 | 0,98% | Opción de venta |
| Anson Funds Management LP | $11 808 000 | 800 000 | 0,98% | Opción de compra |
| BNP PARIBAS FINANCIAL MARKETS | $11 734 200 | 7 950 | 0,98% | Opción de venta |
| JANE STREET GROUP, LLC | $11 058 192 | 749 200 | 0,92% | Opción de compra |
| MORGAN STANLEY | $9 922 380 | 672 248 | 0,83% | Acciones |
| BANK OF AMERICA CORP /DE/ | $9 150 359 | 619 943 | 0,76% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8 339 518 | 565 008 | 0,69% | Acciones |
| JANE STREET GROUP, LLC | $7 462 700 | 505 603 | 0,62% | Acciones |
| Balyasny Asset Management L.P. | $7 380 000 | 500 000 | 0,61% | Opción de venta |
| LMR Partners LLP | $6 642 000 | 450 000 | 0,55% | Opción de venta |
| NOMURA HOLDINGS INC | $6 273 000 | 425 000 | 0,52% | Opción de compra |
| DIADEMA PARTNERS LP | $5 904 000 | 400 000 | 0,49% | Opción de compra |
| Swiss National Bank | $5 319 504 | 360 400 | 0,44% | Acciones |
| XTX Topco Ltd | $5 300 168 | 359 090 | 0,44% | Acciones |
| Ikarian Capital, LLC | $5 235 372 | 354 700 | 0,44% | Opción de venta |
| CITIGROUP INC | $4 659 717 | 315 699 | 0,39% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $4 580 973 | 310 364 | 0,38% | Acciones |
| DAGCO, INC. | $4 351 740 | 1 028 780 | 0,36% | Acciones |
| Everhart Financial Group, Inc. | $4 251 146 | 288 018 | 0,35% | Acciones |
| Rafferty Asset Management, LLC | $3 540 806 | 239 892 | 0,29% | Acciones |
| RHUMBLINE ADVISERS | $3 400 726 | 230 402 | 0,28% | Acciones |
| Walleye Capital LLC | $3 377 088 | 228 800 | 0,28% | Opción de venta |
| GOLDMAN SACHS GROUP INC | $3 125 991 | 211 788 | 0,26% | Acciones |
| TUDOR INVESTMENT CORP ET AL | $3 087 792 | 209 200 | 0,26% | Opción de venta |
| WELLINGTON MANAGEMENT GROUP LLP | $2 992 738 | 202 760 | 0,25% | Acciones |
| BOOTHBAY FUND MANAGEMENT, LLC | $2 982 996 | 202 100 | 0,25% | Opción de venta |
| Jefferies Financial Group Inc. | $2 958 775 | 200 459 | 0,25% | Acciones |
| Jefferies Financial Group Inc. | $2 953 476 | 200 100 | 0,25% | Opción de venta |
| Mariner, LLC | $2 925 609 | 198 212 | 0,24% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $2 895 912 | 196 200 | 0,24% | Opción de compra |
| Bank of New York Mellon Corp | $2 801 212 | 189 784 | 0,23% | Acciones |
| ALPS ADVISORS INC | $2 776 459 | 188 107 | 0,23% | Acciones |
| JANE STREET GROUP, LLC | $2 405 880 | 163 000 | 0,20% | Opción de venta |
| LPL Financial LLC | $2 297 586 | 155 663 | 0,19% | Acciones |
| SIMPLEX TRADING, LLC | $2 274 501 | 154 099 | 0,19% | Acciones |
| BlackRock, Inc. | $2 222 708 | 150 590 | 0,19% | Acciones |
| WELLS FARGO & COMPANY/MN | $2 208 775 | 149 646 | 0,18% | Acciones |
| Vontobel Holding Ltd. | $2 166 207 | 146 762 | 0,18% | Acciones |
| TUDOR INVESTMENT CORP ET AL | $2 069 352 | 140 200 | 0,17% | Opción de compra |
| Vanguard Global Advisers, LLC | $1 918 874 | 130 005 | 0,16% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $1 859 598 | 125 989 | 0,15% | Acciones |
| Caption Management, LLC | $1 845 000 | 125 000 | 0,15% | Opción de venta |
| PROFUND ADVISORS LLC | $1 780 159 | 120 607 | 0,15% | Acciones |
| MetLife Investment Management, LLC | $1 624 810 | 110 082 | 0,14% | Acciones |
| Daiwa Securities Group Inc. | $1 589 652 | 107 700 | 0,13% | Opción de venta |
| Daiwa Securities Group Inc. | $1 512 900 | 102 500 | 0,13% | Acciones |
| DIADEMA PARTNERS LP | $1 476 000 | 100 000 | 0,12% | Opción de venta |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $1 467 144 | 99 400 | 0,12% | Acciones |
| STATE OF WISCONSIN INVESTMENT BOARD | $1 405 300 | 95 210 | 0,12% | Acciones |
| Harvest Investment Services, LLC | $1 394 554 | 94 482 | 0,12% | Acciones |
| ORBIMED ADVISORS LLC | $1 365 300 | 92 500 | 0,11% | Opción de venta |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $1 229 582 | 83 305 | 0,10% | Acciones |
| Invesco Ltd. | $1 104 816 | 74 852 | 0,09% | Acciones |
| Gotham Asset Management, LLC | $1 097 317 | 74 344 | 0,09% | Acciones |
| FULCRUM WEALTH ADVISORS, LLC | $1 081 214 | 73 253 | 0,09% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $998 534 | 236 060 | 0,08% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $978 588 | 66 300 | 0,08% | Acciones |
| Verition Fund Management LLC | $916 596 | 62 100 | 0,08% | Opción de venta |
| OSAIC HOLDINGS, INC. | $889 776 | 60 284 | 0,07% | Acciones |
| FIFTH THIRD BANCORP | $888 404 | 60 190 | 0,07% | Acciones |
| State of New Jersey Common Pension Fund D | $857 069 | 58 067 | 0,07% | Acciones |
| Verition Fund Management LLC | $832 464 | 56 400 | 0,07% | Opción de compra |
| Police & Firemen's Retirement System of New Jersey | $821 630 | 55 666 | 0,07% | Acciones |
| ARIZONA STATE RETIREMENT SYSTEM | $731 388 | 49 552 | 0,06% | Acciones |
| Caption Management, LLC | $728 745 | 49 373 | 0,06% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $722 310 | 48 937 | 0,06% | Acciones |
| Russell Investments Group, Ltd. | $704 494 | 47 730 | 0,06% | Acciones |
| SIG BROKERAGE, LP | $689 292 | 46 700 | 0,06% | Opción de compra |
| Vanguard Investments Australia, Ltd. | $684 643 | 46 385 | 0,06% | Acciones |
| COMMONWEALTH EQUITY SERVICES, LLC | $665 481 | 45 087 | 0,06% | Acciones |
| INSTRUMENTAL WEALTH, LLC | $662 931 | 44 914 | 0,06% | Acciones |
| Persistent Asset Partners Ltd | $655 647 | 758 | 0,05% | Opción de compra |
| Virtus Investment Advisers, LLC | $616 791 | 41 788 | 0,05% | Acciones |
| Accurate Wealth Management, LLC | $614 707 | 47 462 | 0,05% | Acciones |
| AXXCESS WEALTH MANAGEMENT, LLC | $610 665 | 41 373 | 0,05% | Acciones |
| KLP KAPITALFORVALTNING AS | $600 732 | 40 700 | 0,05% | Acciones |
| SJS Investment Consulting Inc. | $590 400 | 40 000 | 0,05% | Acciones |
| Wealthfront Advisers LLC | $587 773 | 39 822 | 0,05% | Acciones |
| Quantinno Capital Management LP | $546 651 | 37 036 | 0,05% | Acciones |
| Visionary Horizons, LLC | $531 360 | 36 000 | 0,04% | Acciones |
| Kestra Advisory Services, LLC | $516 305 | 34 980 | 0,04% | Acciones |
| NORTHSTAR ASSET MANAGEMENT Co | $509 400 | 45 000 | 0,04% | Acciones |
Informantes de la empresa 42 insiders · 17 directivos · 9 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 16 de junio de 2026 A | 1 759 183 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 15 de marzo de 2011 A | 92 994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 7 de enero de 2026 A | 554 327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 20 de abril de 2018 A | — | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 13 de abril de 2011 A | 379 294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 15 de enero de 2009 A | — | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 7 de enero de 2026 A | 557 805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 22 de enero de 2024 A | 40 918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 22 de enero de 2024 A | 117 225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 14 de marzo de 2019 A | — | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 13 de marzo de 2018 A | — | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 15 de marzo de 2011 A | 14 065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 15 de marzo de 2011 A | 41 083 | 0 | 0 | $0 |
| Anastasia Khvorova | Chief Science Officer | 15 de marzo de 2011 A | 60 559 | 0 | 0 | $0 |
| Pamela Pavco | VP of Pharmaceutical Devlpmt | 15 de marzo de 2011 A | 44 940 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 15 de abril de 2010 A | 5 750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 31 de marzo de 2010 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | Consejero | 7 de enero de 2026 A | 154 400 | 1 | 0 | $100 806 |
| John Varian | Consejero | 7 de enero de 2026 A | 72 900 | 0 | 0 | $0 |
| Jane Wasman | Consejero | 7 de enero de 2026 A | 92 900 | 0 | 0 | $0 |
| David A Scheinberg | Consejero | 7 de enero de 2026 A | 73 082 | 0 | 0 | $0 |
| Robert L Van Nostrand | Consejero | 7 de enero de 2026 A | 82 900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | Consejero | 14 de marzo de 2019 A | — | 0 | 0 | $0 |
| Fabio Lopez | Consejero | 12 de junio de 2018 A | — | 0 | 0 | $0 |
| Irving M. Einhorn | — | 10 de octubre de 2017 A | 34 690 | 0 | 0 | $0 |
| William Ashton | — | 10 de octubre de 2017 A | 38 154 | 0 | 0 | $0 |
| Richard Chin | — | 10 de octubre de 2017 A | 31 339 | 0 | 0 | $0 |
| Rudolph Nisi | — | 10 de octubre de 2017 A | 42 918 | 0 | 0 | $0 |
| Sanford Hillsberg | — | 10 de octubre de 2017 A | 56 950 | 0 | 0 | $0 |
| Mary Ann Gray | — | 10 de octubre de 2017 A | 39 167 | 0 | 0 | $0 |
| Stephen S Galliker | — | 10 de octubre de 2017 A | 36 039 | 0 | 0 | $0 |
| Thomas J Knapp | — | 6 de febrero de 2017 A | — | 0 | 0 | $0 |
| Bijan Nejadnik | — | 17 de enero de 2017 A | — | 0 | 0 | $0 |
| Ryan Dunlap | — | 1 de junio de 2016 M | 18 702 | 0 | 0 | $0 |
| Mark W. Schwartz | — | 18 de diciembre de 2015 A | 415 972 | 0 | 0 | $0 |
| Steven A Kriegsman | — | 19 de junio de 2015 A | 5 000 | 0 | 0 | $0 |
| Margaret Kivinski | — | 16 de enero de 2015 A | — | 0 | 0 | $0 |
| Brian L Hamilton | — | 30 de junio de 2014 J | 2 461 | 0 | 0 | $0 |
| Mark J Ahn | — | 30 de junio de 2014 A | 116 225 | 0 | 0 | $0 |
| Rosemary Mazanet | — | 29 de enero de 2013 A | — | 0 | 0 | $0 |
| CYTRX CORP | — | 29 de diciembre de 2010 S | 0 | 0 | 0 | $0 |
| Tod Woolf | — | 15 de enero de 2009 A | — | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 2 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 presentaciones | 10 de octubre de 2018 | — | Presentación inicial | — | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 8 de enero de 2018 | — | Presentación inicial | M&A / venta | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 29 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,77% | 288 499 SH | 8 de agosto de 2026 | Diario |
| IWC · iShares Trust | 0,50% | 640 415 SH | 8 de agosto de 2026 | Diario |
| LABU · Direxion Shares ETF Trust | 0,26% | 268 465 NS | 30 de abril de 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,23% | 316 525 SH | 8 de agosto de 2026 | Diario |
| ICOP · iShares Trust | 0,22% | 126 361 SH | 8 de agosto de 2026 | Diario |
| CANC · Tema ETF Trust | 0,22% | 40 702 NS | 31 de mayo de 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,16% | 202 339 SH | 8 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,14% | 1 712 069 SH | 8 de agosto de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,08% | 1 086 285 SH | 8 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,07% | 4 828 431 SH | 8 de agosto de 2026 | Diario |
| ISCG · iShares Trust | 0,07% | 57 511 SH | 8 de agosto de 2026 | Diario |
| GSSC · Goldman Sachs ETF Trust | 0,05% | 51 293 NS | 31 de mayo de 2026 | N-PORT |
| PICK · iShares, Inc. | 0,04% | 122 564 SH | 8 de agosto de 2026 | Diario |
| ITWO · ProShares Trust | 0,04% | 8 088 NS | 31 de mayo de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,04% | 540 244 SH | 8 de agosto de 2026 | Diario |
| ISCF · iShares Trust | 0,04% | 30 200 SH | 8 de agosto de 2026 | Diario |
| ISCB · iShares Trust | 0,03% | 8 283 SH | 8 de agosto de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2 134 285 SH | 8 de agosto de 2026 | Diario |
| WSML · iShares Trust | 0,03% | 16 889 SH | 8 de agosto de 2026 | Diario |
| RSSL · Global X Funds | 0,03% | 74 459 NS | 30 de abril de 2026 | N-PORT |
| UWM · ProShares Trust | 0,02% | 6 326 NS | 31 de mayo de 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 6 397 NS | 31 de mayo de 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 161 NS | 31 de mayo de 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 64 480 NS | 31 de mayo de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 3 554 NS | 31 de mayo de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 273 812 SH | 8 de agosto de 2026 | Diario |
| IWV · iShares Trust | 0,00% | 43 929 SH | 8 de agosto de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5 908 560 SH | 8 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 15 706 SH | 8 de agosto de 2026 | Diario |